Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis
Mateusz Jacek Spałek,
Jan Poleszczuk,
Anna Małgorzata Czarnecka,
Monika Dudzisz-Śledź,
Aleksandra Napieralska,
Jacek Matysiakiewicz,
Marzanna Chojnacka,
Anna Raciborska,
Aleksandra Sztuder,
Adam Maciejczyk,
Agata Szulc,
Tomasz Skóra,
Bożena Cybulska-Stopa,
Tomasz Winiecki,
Joanna Kaźmierska,
Bartłomiej Tomasik,
Jacek Fijuth,
Piotr Rutkowski
Affiliations
Mateusz Jacek Spałek
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
Jan Poleszczuk
Department for Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland
Anna Małgorzata Czarnecka
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
Monika Dudzisz-Śledź
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
Aleksandra Napieralska
Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland
Jacek Matysiakiewicz
Trauma and Orthopedic Surgery Department, IXth Ward of the District Hospital of Orthopedics and Trauma Surgery in Piekary Slaskie, 41-940 Piekary Slaskie, Poland
Marzanna Chojnacka
Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland
Anna Raciborska
Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, 01-211 Warsaw, Poland
Aleksandra Sztuder
Department of Radiotherapy, Lower Silesian Oncology Centre, 53-413 Wroclaw, Poland
Adam Maciejczyk
Department of Radiotherapy, Lower Silesian Oncology Centre, 53-413 Wroclaw, Poland
Agata Szulc
Department of Radiotherapy, Lower Silesian Oncology Centre, 53-413 Wroclaw, Poland
Tomasz Skóra
Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, 31-115 Kraków, Poland
Bożena Cybulska-Stopa
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 31-115 Kraków, Poland
Tomasz Winiecki
Radiotherapy Department II, Greater Poland Cancer Centre, 61-866 Poznan, Poland
Joanna Kaźmierska
Radiotherapy Department II, Greater Poland Cancer Centre, 61-866 Poznan, Poland
Bartłomiej Tomasik
Department of Radiotherapy, Medical University of Lodz, 92-215 Lodz, Poland
Jacek Fijuth
Department of Radiotherapy, Medical University of Lodz, 92-215 Lodz, Poland
Piotr Rutkowski
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
Background: Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors related to patients’ response to radiation. Methods: We performed a retrospective analysis of patients irradiated for osteosarcoma treatment. We planned to assess differences in the utilization of RT between the periods of 2000–2010 and 2011–2020, identify the risk factors associated with local progression (LP), determine whether RT-related parameters are associated with LP, and calculate patients’ survival. Results: A total of 126 patients with osteosarcoma who received 181 RT treatments were identified. We found a difference in RT techniques between RT performed in the years 2000–2010 and that performed in the years 2011–2020. LP was observed after 37 (20.4%) RT treatments. Intent of RT, distant metastases, and concomitant systemic treatment affected the risk of LP. Five-year overall survival was 33% (95% confidence interval (26%–43%)). Conclusions: RT for osteosarcoma treatment has evolved from simple two-dimensional palliative irradiation into more conformal RT applied for new indications including oligometastatic and oligoprogressive disease. RT may be a valuable treatment modality for selected patients with osteosarcoma.